At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 122 enrolled
Drug / intervention
Bemcentinib +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase Ib/II Multicenter Open-label Study of BGB324 as a Single Agent and in Combination With Cytarabine or Decitabine in Patients With Acute Myeloid Leukemia or as a Single Agent in Patients With Myelodysplastic Syndrome
In Brief
A Phase 2 clinical trial evaluating Bemcentinib, Cytarabine, and 1 other intervention for Acute Myeloid Leukemia and Myelodysplastic Syndromes. Completed, enrolled 122 participants across 12 sites in 4 countries.
Detailed Summary
A Phase Ib/II multicentre open label study of bemcentinib (BGB324) as a single agent in participants with Acute Myeloid Leukemia (AML) or Myelodysplastic syndrome (MDS) or in a combination with cytarabine or decitabine in AML participants. Bemcentinib is a potent selective small molecule inhibitor of AXL a surface membrane protein kinase receptor which is overexpressed in up to half of AML cases.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Myeloid Leukemia, Myelodysplastic Syndromes
CountriesGermany, Italy, Norway, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartOct 2014
First PostedJul 2015
Primary CompletionJun 2022
TodayJul 2026
First PostedJul 2, 2015
Enrollment StartOct 22, 2014
Primary CompletionJun 8, 2022
TodayJul 2, 2026
Enrollment to primary: 7.6 yearsPosted 11 years ago
Interventions
Bemcentinibdrug
Cytarabinedrug
Decitabinedrug